Know Cancer

forgot password

Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

Phase 2
18 Years
Open (Enrolling)
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma

Thank you

Trial Information

Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy


I. To determine the rate of stringent complete response (CR) (sCR) after 8 cycles of CRd (4
cycles of induction + autologous stem cell transplant [ASCT] + 4 cycles of carfilzomib,
lenalidomide, and low dose dexamethasone [CRd] consolidation).


I. Overall response rate defined as partial response or better (>= partial response [PR])
including the rate of very good partial response (VGPR) or better (>= VGPR) and near
complete response or better (sCR/CR/nCR) across entire treatment in high risk and low risk

II. Duration of response (DOR), progression free survival (PFS), time to progression (TTP),
and overall survival (OS).


I. Determination of the rate of minimal residual disease in patients who achieved CR.

II. Prospective evaluation of candidate markers of response to CRd established in the
completed CRd trial.

III. Evaluation of markers of response and duration of response to treatment strategy using
CRd with or without transplant.


INDUCTION THERAPY: Patients receive dexamethasone intravenously (IV) or orally (PO) once
daily (QD) on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9,
15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4
courses in the absence of disease progression or unacceptable toxicity..

TRANSPLANT: Patients undergo autologous stem cell transplant.

CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in
induction. Treatment repeats every 28 days for 4 courses in the absence of disease
progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy
and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days
for 10 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years.

Inclusion Criteria:

- Newly diagnosed, myeloma requiring systemic chemotherapy as per International Myeloma
Working Group (IMWG) uniform criteria:

- Prior treatment of hypercalcemia or spinal cord compression or active and/or
aggressively progressing myeloma with corticosteroids or lenalidomide or
bortezomib-based regimens does not disqualify the patient (the treatment dose
should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period
or not more than 1 cycle)

- Bisphosphonates are permitted

- Suitable and interested to proceed to ASCT

- Measurable disease, prior to initial treatment as indicated by one or more of the

- Serum monoclonal (M)-protein >= 0.5 g/dL

- Urine M-protein >= 200 mg/24 hours

- If serum protein electrophoresis is felt to be unreliable for routine M-protein
measurement, then quantitative immunoglobulin levels are acceptable

- Life expectancy of more than 3 months

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Bilirubin < 1.5 times the upper limit of normal (ULN)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULN

- Absolute neutrophil count (ANC) >= 1.0 x 10^9/L

- Hemoglobin >= 8 g/dL

- Platelet count >= 75 x 10^9/L; subjects may receive red blood cell (RBC) transfusions
or platelet transfusions, if clinically indicated in accordance with institutional
guidelines; however, screening platelet count should be independent of platelet
transfusions for at least 2 weeks

- Calculated or measured creatinine clearance of >= 50 mL/minute, calculated using the
formula of Cockcroft and Gault

- Written informed consent in accordance with federal, local, and institutional

- Females of childbearing potential (FCBP) (defined as sexually mature females who:
have not undergone a hysterectomy or bilateral oophorectomy; or have not been
naturally postmenopausal for at least 24 consecutive months [ie, has had menses at
any time in the preceding 24 consecutive months]) must agree to ongoing pregnancy

- FCBP must have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior
to initiating lenalidomide; the first pregnancy test must be performed within 10-14
days before day 1 cycle 1 and the second pregnancy test must be performed within 24
hours of day 1 cycle 1; the subject may not receive lenalidomide until the treating
investigator has verified that the results of these pregnancy tests are negative, and
must agree to ongoing pregnancy tests as outlined in the protocol

- FCBP must agree to use 2 reliable forms of contraception simultaneously or to
practice complete abstinence from heterosexual intercourse during the following time
periods related to this study:

- For at least 28 days before starting lenalidomide

- While participating in the study; and

- For at least 28 days after discontinuation from the study; the 2 methods of
reliable contraception must include a highly effective method (ie, intrauterine
device (IUD), hormonal [birth control pills, injections, or implants], tubal
ligation, partner's vasectomy) and an additional effective (barrier) method (ie,
latex condom, diaphragm, cervical cap); FCBP must be referred to a qualified
provider of contraceptive methods if needed

- Male subjects must agree to use a latex condom during sexual contact with females of
childbearing potential while participating in the study and for at least 28 days
following discontinuation from the study even if he has undergone a successful

- Male subjects must agree to inform his physician if he has had unprotected sexual
contact with a female who can become pregnant or if he thinks for any reason that his
sexual partner may be pregnant

- Male subjects must agree not to donate semen or sperm while taking lenalidomide

- All study participants must be registered into the mandatory Rev Assist program and
be willing and able to comply with the requirements of Rev Assist

- The ability to take aspirin or other appropriate venous thromboembolism (VTE)

- Subjects must agree to adhere to all study requirements, including birth control
measures and pregnancy testing, visit schedule, outpatient treatment, required
concomitant medications, and laboratory monitoring

Exclusion Criteria:

- Non-secretory or hyposecretory multiple myeloma, prior to initial treatment defined
as < 0.5 g/dL M-protein in serum, < 200 mg/24 hr urine M-protein, or disease only
measured by serum free light chain

- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
skin changes)

- Waldenstrom's macroglobulinemia or immunoglobin (Ig)M myeloma

- Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of
protocol treatment (localized radiotherapy to a single site at least 1 week before
start is permissible)

- Participation in an investigational therapeutic study within 3 weeks or within 5 drug
half-lives (t1/2) prior to first dose, whichever time is greater

- Pregnant or lactating females

- History of allergy to mannitol

- Major surgery within 3 weeks prior to first dose

- Myocardial infarction within 6 months prior to enrollment, New York Heart Association
(NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled
ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active
conduction system abnormalities

- Uncontrolled hypertension or diabetes

- Acute active infection requiring systemic antibiotics, antivirals, or antifungals
within two weeks prior to first dose

- Known or suspected human immunodeficiency virus (HIV) infection, known HIV

- Active hepatitis A, B, or C infection

- Non-hematologic malignancy within the past 3 years except adequately treated basal
cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or
prostate cancer < Gleason grade 6 with stable prostate specific antigen levels or
cancer considered cured by surgical resection alone

- Any clinically significant medical disease or condition that, in the investigator's
opinion, may interfere with protocol adherence or a subject's ability to give
informed consent

- Significant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first
dose and/or within 14 days before enrollment

- Contraindication to any of the required concomitant drugs, including proton-pump
inhibitor (eg, lansoprazole), enteric-coated aspirin, allopurinol or if a history of
prior thrombotic disease, warfarin or low molecular weight heparin

- Subjects in whom the required program of PO and IV fluid hydration is
contraindicated, eg, due to pre-existing pulmonary, cardiac, or renal impairment

- Subjects with known or suspected amyloidosis of any organ

- Subjects with pleural effusions requiring thoracentesis or ascites requiring

- No coverage or not-acceptable by patient co-pay for lenalidomide

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Proportion of patients achieving sCR

Outcome Description:

The proportion of sCR will be reported along with 95% confidence intervals, adjusted for the two-stage nature of the trial design.

Outcome Time Frame:

Day 224

Safety Issue:


Principal Investigator

Andrzej Jakubowiak

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Chicago Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

January 2012

Completion Date:

December 2015

Related Keywords:

  • Stage I Multiple Myeloma
  • Stage II Multiple Myeloma
  • Stage III Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



University of Chicago Comprehensive Cancer Center Chicago, Illinois  60637-1470